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The development of high-throughput technologies such as next-generation sequencing 
(NGS) has allowed for thousands of DNA loci to be interrogated simultaneously in a fast 
and economical method for the detection of clinically deleterious variants. Whenever 
a clinical diagnosis is known, a targeted NGS approach involving the use of disease-
specific gene panels can be employed. This approach is often valuable as it allows for 
a more specific and clinically relevant interpretation of results. Here, we describe the 
customization, validation, and utilization of a commercially available targeted enrichment 
platform for the scalability of clinical diagnostic cardiovascular genetic tests, including 
the design of the gene panels, the technical parameters for the quality assurance 
and quality control, the customization of the bioinformatics pipeline, and the post-
bioinformatics analysis procedures. Regions of poor base coverage were detected and 
targeted by Sanger sequencing as needed. All panels were successfully validated using 
genotype-known DNA samples either commercially available or from research subjects 
previously tested in outside clinical laboratories. In our experience, utilizing several of 
the sub-panels in a clinical setting with 33 real-life cardiovascular patients, we found 
that 20% of tests requested were reported to have at least one pathogenic or likely 
pathogenic variant that could explain the patient phenotype. For each of these patients, 
the positive results may aid the clinical team and the patients in best developing a 
disease management plan and in identifying relatives at risk.
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inTrODUcTiOn
In the clinical genetics setting, most deleterious DNA variants can be detected by DNA sequencing. 
The development of high-throughput technologies such as next-generation sequencing (NGS) has 
allowed for thousands of target regions to be interrogated in a fast and economical approach, when 
compared to the more traditional technique of Sanger sequencing. Different NGS approaches such 
as whole-genome sequencing (WGS) and whole-exome sequencing (WES) have been employed 
especially for gene discovery. In particular, WGS and WES can be used as clinical testing modalities 
when a clinical diagnosis cannot be unequivocally established or for genetic disorders for which 
no other established clinical testing is available. However, when a clinical diagnosis has been 
Table 1 | cardiovascular genetics next-generation sequencing (ngs) panel gene content.
ngs sub-panel number of genes genes covered
Comprehensive cardiomyopathy (CMP) and reflex 
CMP
61 ABCC9, ACTC1, ACTN2, ANKRD1, BAG3, CASQ2, CAV3, CRYAB, CSRP3, CTNNA3, 
DES, DMD, DSC2, DSG2, DSP, DTNA, EMD, EYA4, FHL1, FHL2, FKTN, GATAD1, GLA, 
JPH2, JUP, KLF10, LAMA4, LAMP2, LDB3, LMNA, MYBPC3, MYH6, MYH7, MYL2, 
MYL3, MYLK2, MYOZ2, NEBL, NEXN, PDLIM3, PKP2, PLN, PRKAG2, PSEN1, PSEN2, 
RAF1, RBM20, RYR2, SCN5A, SGCD, TAZ, TCAP, TMEM43, TMPO, TNNC1, TNNI3, 
TNNT2, TPM1, TTN, TTR, VCL
Hypertrophic cardiomyopathy 18 ACTC1, ACTN2, CSRP3, GLA, LAMP2, MYBPC3, MYH7, MYL2, MYL3, MYOZ2, NEXN, 
PLN, PRKAG2, TNNC1, TNNI3, TNNT2, TPM1, TTR
Dilated cardiomyopathy 33 ABCC9, ACTC1, ACTN2, ANKRD1, BAG3, CRYAB, CSRP3, DES, DMD, DTNA, EMD, 
EYA4, GATAD1, LAMP2, LDB3, LMNA, MYBPC3, MYH7, NEXN, PLN, RAF1, RBM20, 
SCN5A, SGCD, TAZ, TCAP, TNNC1, TNNI3, TNNT2, TPM1, TTN, TTR, VCL
Arrythmogenic right ventricular cardiomyopathy 8 CTNNA3, DSC2, DSG2, DSP, JUP, LMNA, PKP2, TMEM43
Marfan syndrome and Loeys–Dietz syndrome 3 FBN1, TGFBR1, TGFBR2
Thoracic aortic aneurysms and dissections (TAAD) 
and reflex TAAD
18 ACTA2, CBS, COL3A1, COL5A1, COL5A2, ELN, FBN1, FBN2, MED12, MYH11, MYLK, 
PLOD1, SLC2A10, SMAD3, SMAD4, TGFB2, TGFBR1, TGFBR2
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reached, a more targeted NGS approach involving the use of 
comprehensive disease-specific gene panels can be employed. In 
the clinical setting for example, gene panels may be designed 
to target genes associated with a disease or a group of related 
diseases depending on the level of complexity of clinical and 
phenotypic overlap. This approach is often valuable as it allows 
for a more specific and clinically relevant interpretation of 
results with variants in genomic loci a  priori selected for their 
disease association. Additionally, when compared to WGS and 
WES, gene panels have the practical benefit of having more 
robust sequence coverage of target loci, lower cost, and faster 
turnaround time (1, 2).
Here, we describe the customization, clinical validation, 
and utilization of a commercial NGS panel, the TruSight One 
(TSO) panel developed by Illumina, Inc., which targets the 
coding regions of 4,813 genes associated with human disease, 
enriching for over 62,000 exons and their splice sites. Although 
NGS is currently considered to be a well-established technique, 
the clinical validation of recently available commercial kits still 
remains a constant challenge and a necessary step to ensure the 
high quality of clinical practice. Here, we show that the method 
of choice was technically reliable for sequencing and base call-
ing, and that the annotation and filtering methods selected 
from the literature successfully detected variants in the targeted 
regions. Target regions were enriched and captured using the 
Illumina Nextera TSO Enrichment Kit and sequenced using 
solid-state sequencing-by-synthesis technology employing the 
Illumina MiSeq desktop sequencer system. The sequencing 
data were processed using an in-house custom bioinformat-
ics pipeline with variant calls generated using the Burrows–
Wheeler Aligner (BWA) followed by GATK analysis, which 
generated a variant call format (.vcf) file to be used for final 
interpretation. We subdivided the TSO panel into six smaller 
panels for testing of the exonic and splicing regions of genes 
associated with cardiovascular diseases according to disease 
phenotype, including arrhythmogenic right ventricular car-
diomyopathy (ARVC), dilated cardiomyopathy/left ventricular 
non-compaction (DCM/LVNC), hypertrophic cardiomyopa-
thy (HCM), Marfan syndrome/Loeys–Dietz syndrome (MFS/
LDS), thoracic aortic aneurysms and dissections (TAAD), 
and a comprehensive cardiomyopathy (CMP) panel. Splitting 
into sub-panels allows for the proper test requisition by the 
physician while minimizing the risk of incidental findings 
and the presence of confounding variants. Several sub-panels 
were designed to have overlapping genes. In addition, the large 
CMP panel allows physicians to request the sequencing of 
genes in a more a comprehensive approach, usually when the 
clinical presentation is not very predictive of a particular type 
of CMP. The performance for each sub-panel was established 
after bioinformatics analyses which detected regions of poor 
coverage. These regions were targeted by Sanger sequencing as 
needed. Overall, all panels were successfully validated using a 
series of available genotype-known samples. We also describe 
our experience utilizing several of the sub-panels in a clinical 
setting with a group of 33 real-life cardiovascular patients (35 
NGS tests requested). In conclusion, the utilization of the 
validated TSO sub-panels has provided us with a method to 
efficiently and economically search for thousands of clinically 
significant variants in one single experiment. Given the success 
of this project, we aim to continue the validation of additional 
sub-panels for other human disorders.
MaTerials anD MeThODs
ngs cardiovascular Panels
The commercial TSO panel consisted of all 4,813 genes. We sub-
divided the gene content of the TSO panel into six clinical NGS 
panels which were further validated. The six clinical NGS panels 
made available for ordering of clinical testing each comprised of 
the sequencing of all coding regions and the immediate flanking 
regions of each exon of a specific group of genes. The CMP and 
the TAAD panels were also made available as reflex options (per 
physician request) when negative results were reported. Table 1 
describes each validated panel and the genes they cover. Table S1 
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in Supplementary Material contains the gene symbol, gene name, 
genomic coordinates, and main gene transcript for each gene that 
was sequenced using one of the NGS panels.
Validation samples
The validation samples consisted of 23 genotype-known and 
3 genotype-unknown samples (Table S2 in Supplementary 
Material). These samples were tested for their ability to result in 
successful libraries and sequence runs, as well as for evaluation 
and validation of the current NGS panel. DNA extraction meth-
odology for each sample is listed in Table S2 in Supplementary 
Material. Validation samples were anonymous Coriell gDNA 
specimens or clinical samples that have been recruited through 
and Indiana University IRB-approved Genetic Registry Specimen 
Repository with minimal description in the report and no listed 
identifiable information.
Patient samples
Patient samples consisted of clinical cases sent to the Indiana 
University School of Medicine Molecular Genetics Diagnostic 
Laboratory of the Department of Medical and Molecular 
Genetics, Indiana University School of Medicine, in the period 
of January 2015 to December 2015, with requisition for testing 
with one the following cardiovascular NGS panels: ARVC, DCM/
LVNC, HCM, MFS/LDS, TAAD, or CMP. Patient samples listed 
in this manuscript have been described without identifiable 
information. All patient DNAs used for testing were extracted 
from whole blood collected in purple-top tube using the Qiagen’s 
Gentra Puregene Blood Kit (Qiagen, Germantown, MD, USA) 
following the manufacturer’s instructions. Samples were de-
identified and only information about the NGS test requested, 
and variants identified were retained for the purpose of analysis 
of results for this manuscript.
Validation runs
Table S3 in Supplementary Material summarizes the scheme 
used to prepare libraries using Illumina’s TSO panel as specified 
by the standard and operating procedure (SOP). Each kit had 
reagents available for three runs. A repeat of NA12878 within 
a run was used for intra-run variability studies. A repeat of 
NA12878 between runs was used for inter-run variability 
studies. Additionally, different operators performed the tests 
according to the established technical protocols and SOP 
guidelines to allow for the evaluation of runs from libraries 
prepared by different operators (A or B). Furthermore, inter-lot, 
inter-day, and inter-run variability were assessed from runs 
of NA11931 between TSO_009 and TSO_013, and runs of 
NA11829 between TSO_010 and TSO_014. Single individuals 
(1-plex) or pools of three individuals (3-plex) were sequenced 
per flow-cell.
library Preparation and sequence Data 
generation
The Illumina TSO NGS panel was developed by Illumina, 
Inc. (San Diego, CA, USA) and includes over 125,395 80-mer 
probes that were designed against the human NCBI GRCh37/
hg19 reference genome assembly. Information about the 
expected performance, targeted regions, content design, and 
other information can be found in the TSO full gene list, TSO 
Data Sheet, and TSO Technical Note in the manufacturer’s 
website.
Optimization and validation experiments were set up manu-
ally following the manufacturer’s instructions. Experiments 
were performed loading either a single sample (1-plex) or three 
samples (3-plex) per MiSeq run per flow-cell. After quantitation 
using Qubit (Thermo Fisher Scientific, Waltham, MA, USA), 
genomic DNA underwent Nextera tagmentation, which con-
verts input genomic DNA into adapter-tagged libraries. Next, 
libraries were denatured and biotin-labeled probes specific to 
the targeted region were used for hybridization. The pool was 
then enriched for the targeted regions by adding streptavidin 
beads that bind to the biotinylated probes. Biotinylated DNA 
fragments bound to the streptavidin-coated beads were mag-
netically pulled down from the solution. The enriched DNA 
fragments were then eluted from the beads and hybridized for 
a second capture. Library preparation underwent quality con-
trol (QC) using an Agilent TapeStation, which was employed 
before library preparation and Qubit quantitation after library 
preparation. These steps provided the necessary metrics to 
assess the efficiency of fragmentation within the desired size 
range and the successful adapters/barcoding addition to each 
sample’s DNA fragment. Prepared libraries were then loaded on 
to a flow-cell for sequencing with the Illumina MiSeq desktop 
sequencer system, which acquired sequencing data points and 
generated a bam and a fastq file for sequence reads. The resulting 
sequence data were submitted to analysis if the data passed the 
acceptance and rejection criteria for analytic runs according to 
manufacturer’s instruction.
bioinformatics Pipeline
To analyze and characterize data generated from targeted re-
sequencing, the following softwares were implemented in our 
bioinformatics pipeline: Trim Galore (version 0.3.2) to remove 
adaptor sequences and low quality reads; BWA (version 0.7.5a) 
(3) to align reads to human reference genome UCSC GRCh37/
hg19; GenomeAnalysisTK-2.8-1 (4, 5) for local realignment, base 
quality recalibration, and variants identification; SAMtools (ver-
sion 0.1.19) (6) and picard-tools-1.105 (http://picard.sourceforge.
net) to manipulate alignment files; VCFtools (version 0.1.10) (7) 
and BEDTools (8) (version 2.17.0) to further process resulted 
variant VCF files; ANNOVAR (revision 529) (9) for annotating 
variants; and Human Gene Mutation Database (HGMD) (10–12) 
professional used for further characterizing variants. R (13) and 
PERL were used for additional data analysis and characterization. 
All data processing steps were compiled into an all-steps-in-one 
bash script. Running scripts and parameters applied are available 
at http://compbio.iupui.edu/group/6/pages/clinicalsequencing. 
Additionally, our target file, the TruSight One Sequencing Panel 
Manifest downloaded from Illumina, can be found at: support.
illumina.com/content/dam/illumina-support/documents/
downloads/productfiles/trusight/trusight-one-manifest-
may-2014.zip.
Following these procedures generated a final report of 
variants from targeted gene regions. The report consisted of 
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variant mapping information, gene annotation, amino acid 
change annotation (synonymous or non-synonymous vari-
ants), variant functional annotation [SIFT, PolyPhen, LRTs, and 
MutationTaster (14–20)], variant evolutionary conservation 
annotation [PhyloP and GERP++ (21–23)], variant pres-
ence and allele frequencies in currently publicly sequenced 
populations (dbSNP identifiers, 1000 Genomes Project allele, 
NHLBI-ESP 6500 exome project), and known disease-related 
functional annotation from the HGMD database. Quality 
parameters such as variant quality, read depth, mapping quality, 
and fisher strand bias were included in the final variants report 
as well (see Table S4 in Supplementary Material). Although the 
TSO panel includes 4,813 genes, in the clinical setting, only the 
genes included in the panel requested by the referring physician, 
genetic counselor, or other appropriate health care provider 
were analyzed and only variants for the requested panel were 
available for post-bioinformatics analyses of variants. Further 
information regarding the bioinformatics pipeline, can be 
found in the Supplementary Material.
Post-bioinformatics analyses
The TSO sequencing panel was first tested in 3-plex experi-
ments (three individuals pooled per flow-cell run), as specified 
by the manufacturer. Validation of coverage and SNP perfor-
mance was completed using 3-plex and 1-plex runs. Variants 
found in the validation samples were compared to secondary 
data as specified in Table S2 in Supplementary Material for 
concordance and evaluation of several metrics including false 
positive (FP) and false negative (FN) rates, analytic sensitiv-
ity, analytic specificity, overall genotype concordance (OGC), 
non-reference sensitivity (NRS), non-reference discrepancy 
(NRD), non-reference genotype concordance (NRGC), and 
precision.
Samples received for clinical testing were run as 1-plex or 
3-plex NGS panel experiments (panel selection as requested 
for each patient). Sanger (BigDye) sequencing was used to 
provide data for bases with insufficient coverage in exonic 
and splicing (±2 nucleotides from the exon) regions of genes 
of interest in the NGS panel run (<15× or <10× sequence 
depth, as needed). Several regions were recurrently found 
to have lower than 15× sequence depth in 1-plex validation 
runs (Table S5 in Supplementary Material) and were included 
in the default Sanger sequencing for clinical testing for each 
selected panel. “Products were sequenced using an Applied 
Biosystems 3500 xl Genetic Analyzer in conjunction with the 
ABI BigDye® Terminator v3.1 Cycle Sequencing kit chemistry 
and protocol (ABI, Foster City, CA). Sequences where aligned 
to each gene and analyzed using Mutation Surveyor software 
V4.0.7 (SoftGenetics, State College, PA).” The limitations of 
the Sanger sequencing method are that the presence of DNA 
structural rearrangements (such as the deletion of an exon 
or multiple exons) may not be detected by sequence analysis. 
Additional tests analyzing DNA structural rearrangements 
should be recommended to those patients who are negative for 
sequencing analysis. Additionally, variants that may be found 
within known segmental duplication (SegDup) regions listed 
in Table S6 in Supplementary Material cannot be amplified and 
sequenced unambiguously by PCR and BigDye sequence, and 
therefore cannot be reported. Variants found outside those loci 
listed in Table S6 in Supplementary Material were attempted to 
be confirmed unambiguously by PCR and BigDye sequencing 
if they were classified as pathogenic/likely pathogenic or variant 
of uncertain clinical significance (VUS).
Variants found in clinical test samples were evaluated for 
their clinical effect as being pathogenic, likely pathogenic, 
gene modifier, VUS, likely benign, or benign as explained in 
the Supplementary Material (special cases may differ from the 
classification procedures). The first step included separating the 
variants based on their presence or absence in the HGMD data-
base, in order to facilitate the review process, since the HGMD 
database provides some curation for variants with known disease 
association. Variants deemed to be pathogenic/likely pathogenic 
or VUS were confirmed by Sanger sequencing as deemed neces-
sary by the laboratory director on a case-by-case basis. In our 
post-bioinformatics analysis, we have mostly adhered to the 
current American College of Medical Genetics and Genomics 
(ACMG) guidelines for the standard interpretation of genetic 
variants (24). However, some parameters such as frequency 
have been adapted to reflect the current knowledge about 
the increased complex inheritance pattern in several cardiac 
syndromes, previously regarded as pure monogenic Mendelian 
diseases such as dilated cardiomyopathy (DCM), HCM, and 
ARVC, in which 5–10% of cases can present with two or more 
deleterious variants (25).
resUlTs
Panel Validation
Six NGS panels comprising of a select group of genes from the 
Illumina, Inc. TSO panel was optimized and validated using 
our in-house bioinformatics approach as described in Section 
“Materials and Methods.” Table 2 summarizes the metrics of the 
validation studies. Overall, the validation data for the NGS TSO 
and the cardiovascular sub-panels gave consistent and accurate 
genotype calls. A more detailed explanation of the validation 
results found in Table 2 is presented below.
Coverage
The overall coverage (sequence depth) of target bases for the 
TSO panel (see Figure  1) was dependent on the concentra-
tion of final library used in the sequencing run (compare 
TSO_002_NA12878 15 versus 18pM runs) as well as on the 
final number of samples pooled per  sequencing run (compare 
for example, NA11829 in 3-plex run TSO_010 and in 1-plex 
run TSO_014). The same was true for all cardiovascular sub-
panels as summarized on Table 2. Overall, better coverage was 
obtained from higher concentration of library used in the run 
and in 1-plex experiments (as was found later for patient runs). 
Regions of systematic low coverage were often found to fall 
within the first exon of the targeted genes, likely due to high GC 
content in these regions, which may affect probe binding. Other 
factors, such as an inherent suboptimal performance of certain 
capture probes, may also play a role in the decreased coverage 
of some regions; however, since the TSO panel is a commercial 
Table 2 | summary of validation for next-generation sequencing Trusight One (TsO) and cardiovascular sub-panels.
1-Plex experiment (average of experiments ± sD)
Metricsb TsO panel (full) comprehensive 
cardiomyopathy (cMP) 
and reflex
hypertrophic 
cardiomyopathy 
(hcM)
Dilated 
cardiomyopathy/left 
ventricular  
non-compaction 
(DcM/lVnc)
arrhythmogenic 
right ventricular 
cardiomyopathy 
(arVc)
Marfan syndrome/
loeys–Dietz 
syndrome (MFs/
lDs)
Thoracic aortic 
aneurysms and 
dissections (TaaD)  
and reflex
Target region mean depth (x) 301.25 ± 35.56 309 ± 37.7 277 ± 30.38 322 ± 39.71 319.75 ± 43.22 240.25 ± 28.55 292.75 ± 32.84
Fraction of regions target depth ≥15× 0.97 ± 0.00 0.99 ± 0.00 1.00 ± 0.00 0.99 ± 0.00 0.99 ± 0.00 0.99 ± 0.00 0.99 ± 0.00
Accuracy 100% 100% 100% 100% 100% 100% 100%
Analytical sensitivity 0.96 ± 0.01 0.96 ± 0.02 1.00 ± 0.00 0.95 ± 0.03 0.98 ± 0.04 1.00 ± 0.00 0.96 ± 0.03
Analytical specificity 0.89 ± 0.03 0.93 ± 0.03 0.92 ± 0.04 0.93 ± 0.03 0.91 ± 0.05 1.00 ± 0.00 0.99 ± 0.02
False negative (FN) SNP rate 0.04 ± 0.01 0.04 ± 0.02 0.00 ± 0.00 0.05 ± 0.03 0.02 ± 0.04 0.00 ± 0.00 0.04 ± 0.03
False positive (FP) SNP rate 0.11 ± 0.03 0.07 ± 0.03 0.08 ± 0.04 0.07 ± 0.03 0.09 ± 0.05 0.00 ± 0.00 0.01 ± 0.02
Overall genotype concordance (OGC) range 0.81–0.94 0.82–0.94 0.83–1.00 0.81–0.97 0.81–1.00 N/Aa 0.87–1.00
Non-reference sensitivity (NRS) range 0.91–0.98 0.87–1.00 0.94–1.00 0.86–1.00 0.81–1.00 N/Aa 0.89–1.00
Non-reference discrepancy (NRD) range 0.07–0.20 0.06–0.19 0.00–0.17 0.04–0.20 0.00–0.19 N/Aa 0.00–0.13
Non-reference genotype concordance (NRGC) 
range
0.90–0.97 0.87–1.00 0.94–1.00 0.86–1.00 0.81–1.00 N/Aa 0.89–1.00
Precision range 0.85–0.97 0.86–0.98 0.85–1.00 0.87–1.00 0.81–1.00 N/Aa 0.95–1.00
Number of loci with >15× coverage (length in 
basepairs)c
Not assessed 34 (3,329 bp) 3 (221 bp) 21 (1,561 bp) 6 (423 bp) 1 (100 bp) 6 (787 bp)
Number of SegDups loci (length in basepairs)d Not assessed 5 (1,914 bp)
2e (197 bp)
0 (0 bp) 2 (208 bp)
0e (0 bp)
2 (197 bp) 0 (0 bp) 6 (1,917 bp)
1e (173 bp)
3-Plex experiment (average of experiments ± sD)
Metricsb TsO panel cMP and cMP reflex hcM DcM/lVnc arVc MFs/lDs TaaD and TaaD reflex
Target region mean depth (x) 117.48 ± 11.92 118.03 ± 10.42 108.41 ± 12.01 122.66 ± 10.57 124.07 ± 11.58 94.48 ± 9.75 114.76 ± 11.74
Fraction of regions target depth ≥15× 0.95 ± 0.01 0.98 ± 0.00 0.98 ± 0.01 0.98 ± 0.00 0.97 ± 0.01 0.98 ± 0.01 0.98 ± 0.00
Accuracy (%) 100 100 100 100 100 100 100
Analytical sensitivity 0.96 ± 0.01 0.96 ± 0.03 0.99 ± 0.02 0.94 ± 0.03 0.98 ± 0.04 0.97 ± 0.09 0.97 ± 0.04
Analytical specificity 0.89 ± 0.03 0.93 ± 0.03 0.88 ± 0.03 0.94 ± 0.03 0.91 ± 0.06 0.98 ± 0.06 0.96 ± 0.04
FN SNP rate 0.04 ± 0.01 0.04 ± 0.03 0.01 ± 0.02 0.06 ± 0.03 0.02 ± 0.04 0.03 ± 0.09 0.03 ± 0.04
FP SNP rate 0.11 ± 0.03 0.07 ± 0.03 0.12 ± 0.08 0.06 ± 0.03 0.09 ± 0.06 0.02 ± 0.06 0.04 ± 0.04
OGC range 0.81–0.94 0.82–0.94 0.83–1.00 0.81–0.97 0.81–1.00 N/Aa 0.87–1.00
NRS range 0.91–0.98 0.87–1.00 0.94–1.00 0.86–1.00 0.81–1.00 N/Aa 0.89–1.00
NRD range 0.07–0.20 0.06–0.19 0.00–0.17 0.04–0.20 0.00–0.19 N/Aa 0.00–0.13
NRGC range 0.90–0.97 0.87–1.00 0.94–1.00 0.86–1.00 0.81–1.00 N/Aa 0.89–1.00
Precision range 0.85–0.97 0.86–0.98 0.85–1.00 0.87–1.00 0.81–1.00 N/Aa 0.95–1.00
aQuantitative measurements OGC, NRS, NRD, NRGC, and precision were not computed for the MFS/LDS panel since only three variants were available for these analyses, and there was not enough power for the performance of the 
quantitative measurements above. Qualitative measurements of quality control for library preparation, sequencing performance, coverage, and SNP performance indicated that the variability among the runs listed above were within 
acceptable range.
bSamples MotherLP and ProbandJP were not used in the calculations of FN SNP rate, FP SNP rate, analytic sensitivity, analytic specificity, OGC, NRS, NRD, NRGC, and precision range. Only GenReg samples were used in accuracy 
calculations.
cNumber of loci (with corresponding length in basepairs in parenthesis) that presented with lower than 15× coverage after 1-plex runs.
dNumber of loci (with length in basepairs in parenthesis) that mapped to a region of known segmental duplications (SegDups).
eNumber of loci (with corresponding number of basepairs in parenthesis) with known SegDup that were successfully validated to be unambiguously amplified and sequenced out of the total regions and corresponding basepairs listed.
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FigUre 1 | Trusight One (TsO) next-generation sequencing depth in all validation runs. Sequencing depth, x.
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off-the-shelf product, we were not given the choice to add 
custom optimized probes to mitigate this problem. Regions of 
less than 15× depth of coverage from 1-plex experiments were 
selected for BigDye (Sanger) sequencing validation for each 
panel (number and length of loci are listed in Table  2). Loci 
pertaining to regions of known SegDups for each panel were 
also attempted to be validated. It is possible that additional 
loci may need to be Sanger sequenced after NGS testing of 
a given patient (for example, for confirmation or for testing 
of additional regions with low coverage or within SegDups).
Accuracy
De-identified DNA samples with various genotypes previously 
tested at an independent clinical laboratory were assayed. The 
assay showed complete concordance with expected results for all 
panels, following a blinded analysis. These results show valida-
tion of the TSO panel (and its sub-panels), of the bioinformatics 
pipeline, and of the post-bioinformatics filtering of variants. In 
addition, using a 1-plex run with NA12878 (TSO_002_18pM 
run), we determined the maximum length of indels properly 
detected by the TSO panel to be of 22 nucleotides in a homozygous 
Table 3 | corrected snP performance validation in 1-plex comprehensive comprehensive cardiomyopathy (cMP) panel validation after bigDye 
sequencing.
Metrics Trusight 
One panel
cMP and 
reflex
hypertrophic 
cardiomyopathy
Dilated 
cardiomyopathy/
left ventricular 
non-compaction
arrhythmogenic 
right ventricular 
cardiomyopathy
Marfan 
syndrome/
loeys–Dietz 
syndrome
Thoracic aortic 
aneurysms and 
dissections and 
reflex
Analytical sensitivity N/Aa 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 N/Aa 1.00 ± 0.00
Analytical specificity N/Aa 0.99 ± 0.00 1.00 ± 0.00 0.99 ± 0.00 1.00 ± 0.00 N/Aa 1.00 ± 0.00
False negative (FN) SNP rate N/Aa 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 N/Aa 0.00 ± 0.00
False positive (FP) SNP rate N/Aa 0.01 ± 0.00 0.00 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 N/Aa 0.00 ± 0.00
aMeasurements not calculated for the designated panels (no BigDye sequencing performed).
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state, and 30 nucleotides in a heterozygous state (both cases with 
satisfactory quality and sequence depth; see indel information in 
Materials and Methods in Supplementary Material).
Analytical Sensitivity, Analytical Specificity, FN Rates, 
and FP Rates
Table  2 lists the analytical sensitivity, analytical specificity, FN 
rates, and FP rates obtained in 1-plex and 3-plex NGS valida-
tion experiments when the data obtained (from a run, prior to 
BigDye confirmation) were compared to data from an outside 
source. Samples MotherLP and ProbandJP were not used in these 
calculations. Overall, very similar analytical sensitivity, analytical 
specificity, FN rates, and FP rates were obtained between 1-plex 
and 3-plex experiments.
BigDye confirmation was performed to test the FP and FN 
variants found in 1-plex experiments. Following BigDye con-
firmation, the results for 1-plex experiments shown in Table 2 
were corrected to reflect the final analytical sensitivity, analytical 
specificity, and FN and FP rates for the exonic and splicing tar-
geted regions that obtained sequence depth of ≥15× of genes in 
the six NGS panels (Table 3). The values in Table 3 represent the 
true expected reportable performance of the six NGS panels for 
1-plex runs (since exonic and splicing regions of genes with <15× 
or <10× sequence depth were covered by BigDye sequencing, as 
deemed necessary). With an average of 1, 0.996, 0, and 0.004 for 
the sensitivity, specificity, FN rate, and FP rate, respectively, our 
panels demonstrated an excellent performance for the clinical 
application.
Assay Precision
The overall precision of each panel was calculated by running 
three different samples various times. Runs were compared to 
secondary data available (Illumina Platinum Genomes and 1000 
G project) and also to a series of repeated runs in our laboratory. 
The repeatability was tested by the intra-run variability (two 
libraries of the same starting genomic DNA sample run twice in 
the same sequencing experiment), while the reproducibility was 
tested by the inter-run variability (two libraries of the same start-
ing genomic DNA sample run twice in the separate sequencing 
experiments). Additionally, inter-operator variability was tested 
by allowing operator A to perform experiment TSO_004 while 
operator B performed experiment TSO_005. Furthermore, inter-
lot, inter-day, and inter-run variability were assessed from runs of 
NA11931 between TSO_009 and TSO_013, and runs of NA11829 
between TSO_010 and TSO_014. Several measurements were 
used to assess variability. The OGC, NRS, NRD, and NRGC were 
computed as previously published (26, 27). OGC, NRS, NRD, 
and NRGC were calculated treating each replicate alternatively 
as comparison set and evaluation set. Precision was calculated 
as True Positive SNPs divided by SNPs obtained from the Miseq 
run. Table 2 describes the range of each measurement for both 
MiSeq runs compared to secondary data and to MiSeq repeated 
runs. Overall, values obtained from comparing our TSO NGS 
experiments to other methods used by secondary testing sites 
showed more variability than when comparing to our repeated 
runs (Table S7 in Supplementary Material).
Assay Robustness
DNAs obtained from different sources (whole blood, cell 
lines, buccal swabs, and frozen post-mortem blood) passed 
all QC steps from DNA extraction to library preparation, 
to required MiSeq sequencing metrics. Only one MiSeq 
instrument is available in our molecular genetics laboratory. 
Table  S2 in Supplementary Material summarizes the various 
runs performed and Table 2 summarizes the precision obtained 
under various conditions. It is evident that this assay is suf-
ficiently robust to accommodate variations among consumables, 
technologists, and origin of DNA. However, assessment of the 
impact of contaminants on the performance of the test has not 
been systematically performed.
Patient Testing
Results from de-identified patient samples received by our 
clinical laboratory in the period of January 2015 to December 
2015 with requisition for testing using one the cardiovascular 
NGS panels were collected. The patient reported results and 
variants found per panel requested are detailed in Table S8 in 
Supplementary Material. Overall, we were requested to perform 
NGS tests for 33 patients in the period selected for the writing 
of this manuscript, with two patients (IDs 24 and 32) having 
sequencing reported for two panels (CMP as a reflex). The distri-
bution of the type of panel requested reflects the specific patient 
population of the requesting health professional, for which they 
deem to have the necessity to order a clinical genetic testing. 
Out of the 35 panels requested for testing, about half (18) were 
CMP panels. The second most ordered NGS test was the TAAD 
panel (10, or 29%). There were no requests for the ARVC panel 
during the period selected (Figure 2). Overall, 20% of all tests 
FigUre 2 | Distribution of panels ordered for patient testing (%). 
The ARVC panel was not ordered for patient testing during the time-frame 
selected. Two patients (IDs 24 and 32) had sequencing reported for two 
panels (CMP as a reflex). ARVC, arrhythmogenic right ventricular 
cardiomyopathy panel; CMP, comprehensive cardiomyopathy panel; DCM/
LVNC, dilated cardiomyopathy/left ventricular non-compaction panel; 
HCM, hypertrophic cardiomyopathy panel; MFLS, Marfan syndrome/
Loeys–Dietz syndrome panel; TAAD, thoracic aortic aneurysms and 
dissections panel.
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requested resulted in a positive result, meaning that at least one 
pathogenic or likely pathogenic variant was found in the patient 
tested. The CMP panel had the highest positive result rate with 
28% of patients tested being reported to have at least one variant 
that could explain their phenotype. Additionally, about 43% of 
all NGS tests were reported to have no pathogenic or likely 
pathogenic variants, but to have at least one VUS, and about 
37% of panels tested had a negative result (no pathogenic, likely 
pathogenic, or VUS was found). All HCM panels were reported 
as negative; however, only two HCM panels were requested 
in the period analyzed (Figure  3). Figure  3 shows a graphic 
representation of our clinical sample population pick-up rates. 
Overall, the positive rate of approximately 28% obtained for 
the CMP panel (our largest sample size) is consistent with the 
previously published expected positive rate of 30% for patients 
diagnosed with DCM—we compare the published DCM rate to 
our CMP rate since in most cases, when the ordering physicians 
for our patients suspected a diagnosis of DCM they tended 
to order the larger, more comprehensive CMP panel (28). For 
other panels, the positive rates were heavily dependent on the 
diagnostic criteria and interpretation of clinical presentation 
used by the clinician prior to patient genetic testing. Additionally, 
in many cases, the panel requested by the physician may have 
been used as a differential diagnosis to exclude a specific disease. 
Therefore, the rate we obtained for the HCM, MFLS, TAAD, and 
DCM/LVNC panels may not be an accurate representation of 
expected pick-up rates for a given definitively diagnosed patient 
population.
DiscUssiOn
Sequencing information may be used as an aid to clinicians in 
determining disease diagnosis, follow-up procedures, genetic 
counseling, therapeutic strategy, and treatment of disorders 
based on variants found in the gene(s) analyzed. Laboratory-
developed NGS panel tests can identify an individual’s genotype 
from genomic DNA with focus on specific disorders, groups 
of genes, phenotypes, and other variables in an efficient and 
cost-effective way. In this study, we present our results from 
the optimization and validation of the Illumina TSO NGS 
panel utilizing the Illumina MiSeq and an in-house bioinfor-
matics pipeline for clinical testing of cardiovascular disorders 
(including HCM, DCM/LVNC, ARVC, MFS/LDS, TAAD, and 
comprehensive CMP). Our validation demonstrated that our 
procedures fulfilled the requirements of a clinical assay for 
detection of nucleotide base alterations, and small deletions 
and insertions with a desirable clinical test level of quality to 
detect constitutive genomic variants. Compared to the use 
of Sanger sequencing, at the current pricing and established 
turnaround time for clinical samples at our laboratory, one 
would save approximately 9.5 times the cost, and 10.2 times the 
time when using our NGS approach for an average gene, such 
as LMNA. Compared to other NGS targeting technologies, the 
hybridization capture-based approach that we used (as opposed 
to amplicon-based approach) allowed us to obtain a high qual-
ity NGS panel with clinically acceptable sensitivity, specificity, 
accuracy, precision, and coverage. Previous studies have shown 
that amplicon methods tend to be suboptimal and may generate 
higher FP and FN rates as well as lower coverage and uniform-
ity (29). Finally, with regards to our optimized bioinformatics 
pipeline, we employed the most widely used tools to identify 
variants following the best practices of the GATK. Although, to 
our knowledge, there is no single state-of-the-art pipeline that is 
currently available for clinical NGS panel studies, our validation 
studies of our in-house developed bioinformatics pipeline have 
also shown clinically acceptable high quality results. A limita-
tion of our study is that it is based on a small sample size, which 
may render it to be of insufficient power to address the genotypic 
variability of future samples and the true analytic sensitivity and 
specificity. Future studies are necessary to increase the power of 
our current assessment.
Our sub-panel approach included the selection of genes asso-
ciated with cardiovascular diseases according to disease pheno-
type. Among the genes selected for each panel, several belong 
to a list of known pathogenic (KP) and/or expected pathogenic 
(EP) actionable variants, according to the ACMG recommenda-
tions on incidental findings: 18 genes with actionable KP/EP 
variants out of 61 CMP panel genes (MYBPC3, MYH7, TNNT2, 
TNNI3, TPM1, MYL3, ACTC1, PRKAG2, GLA, MYL2, LMNA, 
RYR2, PKP2, DSP, DSC2, TMEM43, DSG2, and SCN5A), 10/18 
HCM panel genes (MYBPC3, MYH7, TNNT2, TNNI3, TPM1, 
MYL3, ACTC1, PRKAG2, GLA, and MYL2), 8/33 DCM/LVNC 
panel genes (MYBPC3, MYH7, TNNT2, TNNI3, TPM1, ACTC1, 
LMNA, and SCN5A), 6/8 ARVC panel genes (LMNA, PKP2, 
DSP, DSC2, TMEM43, and DSG2), 3/3 MFS/LDS panel genes 
(FBN1, TGFBR1, and TGFBR2), and 8/18 TAAD panel genes 
(COL3A1, FBN1, TGFBR1, TGFBR2, SMAD3, ACTA2, MYLK, 
and MYH11) (30).
In our experience with 33 patients referred for clinical genetic 
testing using the given NGS panels, we found a positive result 
FigUre 3 | reported results per panel requested. Final patient panel results were reported as either being positive (at least one pathogenic or likely pathogenic 
variant was found), VUS (at least one VUS but no pathogenic or likely pathogenic variant was found), or negative (no pathogenic, likely pathogenic, or VUS was 
found). The ARVC panel was not ordered for patient testing during the time-frame selected. Two patients (IDs 24 and 32) had sequencing reported for two panels 
(CMP as a reflex) Percentages are shown followed by the actual number of reports of each category in parenthesis. ARVC, arrhythmogenic right ventricular 
cardiomyopathy panel; CMP, comprehensive cardiomyopathy panel; DCM/LVNC, dilated cardiomyopathy/left ventricular non-compaction panel; HCM, hypertrophic 
cardiomyopathy panel; MFLS, Marfan syndrome/Loeys–Dietz syndrome panel; TAAD, thoracic aortic aneurysms and dissections panel; VUS, variant of uncertain 
clinical significance.
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(pathogenic or likely pathogenic variant) for 20% of the panels 
tested. The highest positive rate resulted from CMP panels (28%), 
which was also the NGS panel that was the most requested in 
the period analyzed (51% of all panels requested). Patients with a 
positive test result may have a more appropriate management of 
their clinical phenotype and they were, as well as their relatives, 
recommended to receive continued clinical evaluation, follow-up, 
and genetic counseling. Our laboratory offers targeted testing for 
the specific variant(s) detected in the proband to at-risk relatives 
using Sanger sequencing technology, and many of the families 
took advantage of this service.
From the 33 patients referred for clinical genetic testing using 
the given NGS panels, about 43% of all tests were reported to have 
at least one VUS, but not a definitive pathogenic or likely patho-
genic variant. The functional significance of these variants is not 
known at present and their contribution to the patient’s disease 
phenotype could not be determined at the time of reporting. 
However, these VUSs are good candidates for functional studies, 
and the analysis of other affected relatives of the patient tested 
may help support a potential pathogenic role of these variants 
if they co-segregate with the disease phenotype in the families 
studied.
From the 33 patients referred for clinical genetic testing using 
the given NGS panels, about 37% of all tests were reported to 
be negative. Many reasons may be related to a negative result. 
For example, a complicated clinical phenotype, or confounding 
factors such as environmental causes may result in a challenging 
choice for the most appropriate test to run in order to achieve the 
diagnosis of the proband. On the laboratory side, there are several 
technical limitations that could be associated with negative results. 
For example, the enrichment design employed in the commercial 
kit used for our NGS assays targets and detects variants in the 
10
Celestino-Soper et al. Validation of NGS Panel for Cardiovascular Testing
Frontiers in Cardiovascular Medicine | www.frontiersin.org March 2017 | Volume 4 | Article 11
coding sequence and adjacent splicing and intronic sequences of 
the desired genes, while variants in deep intronic, non-coding, 
and regulatory regions that could affect gene expression were not 
targeted by our NGS assays. In addition, our clinical NGS tests 
were not designed for the purpose of detecting copy number vari-
ants due to large deletions and duplications encompassing all or a 
large portion of a gene (the maximum length of indels we detected 
was of 23 nucleotides in a homozygous state and 31 nucleotides 
in a heterozygous state). Moreover, our NGS methodology and 
depth of coverage were designed for constitutional genetics and 
may not detect low level mosaicism. Likewise, there could be 
some coding and splice site regions of genes that may present 
with an intrinsic sequence characteristics leading to suboptimal 
data. Finally, although our panels have been designed to include 
the great majority of genes known to be involved in each of the 
cardiovascular disorders listed here, every day, scientific progress 
reveals new genes that may be causing or be associated with these 
diseases. A benefit of our sub-panel design approach, in which 
a large panel was subdivided into smaller panels, is the fact that 
new genes and new sub-panels may be quickly validated from the 
list of 4,813 genes in the TSO panel as new literature points to new 
genes being involved in cardiovascular diseases. This validation 
would only consist of developing Sanger sequencing for regions 
of systematic low coverage and regions of known SegDups for 
the new genes and the calculation of parameters, such as FN, FP, 
accuracy, sensitivity, and specificity. For example, we are cur-
rently working on the validation and clinical implementation of 
NGS sub-panels for testing in Noonan spectrum disorders, long 
QT syndrome, hypertension, lipid disorders, and comprehensive 
arrhythmias. Additionally, our TSO panel and validation strategy 
may be used in the future for an array of non-cardiovascular 
diseases, including neurological, metabolic, skeletal disorders, 
and cancer, to name a few.
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